• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

84.97 +2.84 (+3.46%)
Streaming Delayed Price Updated: 12:35 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
June 15, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
June 14, 2025
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth... 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
June 10, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
May 06, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
February 27, 2025
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
June 06, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
June 02, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
May 28, 2025
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
May 28, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
May 27, 2025
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
May 22, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
May 22, 2025
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
May 18, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
May 13, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
May 09, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday ↗
May 09, 2025
 
Via Benzinga
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
May 07, 2025
 
Via Benzinga
News headline image
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
May 07, 2025
 
Via Benzinga
News headline image
PTC Therapeutics (PTCT) Q1 2025 Earnings Call ↗
May 06, 2025
Via The Motley Fool
News headline image
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? ↗
May 05, 2025
PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
May 05, 2025
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
May 05, 2025
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
May 05, 2025
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
May 05, 2025
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
April 22, 2025
 
Via Benzinga
News headline image
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder ↗
March 28, 2025
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review. 
Via Benzinga
News headline image
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July ↗
March 20, 2025
PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025. 
Via Benzinga
News headline image
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
March 11, 2025
 
Via Benzinga
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
December 10, 2024
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
News headline image
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗
December 06, 2024
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap